Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer

The purpose of this study was to quantify circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients, and to demonstrate the role of CTCs in cancer therapy. This study investigates the hypothesis that CTCs can predict clinical outcomes in patients with AGC. From November 2007 to June 2...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2010-04, Vol.101 (4), p.1067-1071
Main Authors: Matsusaka, Satoshi, Chìn, Keisho, Ogura, Mariko, Suenaga, Mitsukuni, Shinozaki, Eiji, Mishima, Yuji, Terui, Yasuhito, Mizunuma, Nobuyuki, Hatake, Kiyohiko
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Automation
Biological and medical sciences
Biomarkers
Bone marrow
Breast cancer
Cancer therapies
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cytokeratin
Disease-Free Survival
Drug Combinations
Female
Gastric cancer
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Metastasis
Middle Aged
Neoplastic Cells, Circulating
Original
Oxonic Acid - therapeutic use
Paclitaxel
Paclitaxel - administration & dosage
Patients
Prospective Studies
Response rates
Stomach Neoplasms - blood
Stomach Neoplasms - drug therapy
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tegafur - therapeutic use
Treatment Outcome
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to quantify circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients, and to demonstrate the role of CTCs in cancer therapy. This study investigates the hypothesis that CTCs can predict clinical outcomes in patients with AGC. From November 2007 to June 2009, 52 patients with AGC were enrolled into a prospective study. The chemotherapy regimen was an S‐1‐based regimen (S‐1 with or without cisplatin) or paclitaxel. CTCs of whole blood at baseline, 2 weeks, and 4 weeks after initiation of chemotherapy, were isolated and enumerated using immunomagnetics. Patients with ≥4 CTCs at 2‐week points and 4‐week points had a shorter median progression‐free survival (PFS) (1.4, 1.4 months, respectively) than those with the median PFS of
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/j.1349-7006.2010.01492.x